Key factors in the acquisition of contrast kinetic data for oncology.
about
Advanced techniques using contrast media in neuroimagingCreation of DICOM--aware applications using ImageJAdded Value of Assessing Adnexal Masses with Advanced MRI TechniquesProApolipoprotein A1: a serum marker of brain metastases in lung cancer patientsPractical dynamic contrast enhanced MRI in small animal models of cancer: data acquisition, data analysis, and interpretationSimultaneous mapping of blood volume and endothelial permeability surface area product in gliomas using iterative analysis of first-pass dynamic contrast enhanced MRI data.Incorporating a vascular term into a reference region model for the analysis of DCE-MRI data: a simulation studyA theoretical framework to model DSC-MRI data acquired in the presence of contrast agent extravasation.Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imagingA new ex vivo method to evaluate the performance of candidate MRI contrast agents: a proof-of-concept study.Temporal resolution and SNR requirements for accurate DCE-MRI data analysis using the AATH model.Magnetic resonance imaging of hypoxic injury to the murine placentaVascular effects, efficacy and safety of nintedanib in patients with advanced, refractory colorectal cancer: a prospective phase I subanalysisDiagnosis of suspicious breast lesions using an empirical mathematical model for dynamic contrast-enhanced MRI.Dynamic contrast-enhanced imaging techniques: CT and MRIQuantification of antiangiogenic and antivascular drug activity by kinetic analysis of DCE-MRI data.Response of HT29 colorectal xenograft model to cediranib assessed with 18 F-fluoromisonidazole positron emission tomography, dynamic contrast-enhanced and diffusion-weighted MRI.Magnetic resonance imaging: a potential tool in assessing the addition of hyperthermia to neoadjuvant therapy in patients with locally advanced breast cancerMagnetic resonance imaging of the liver: New imaging strategies for evaluating focal liver lesions.Molecular imaging in cancer treatment.Transmit B1+ field inhomogeneity and T1 estimation errors in breast DCE-MRI at 3 tesla.The use of dynamic tracer concentration in veins for quantitative DCE-MRI kinetic analysis in head and neck.A perspective on vascular disrupting agents that interact with tubulin: preclinical tumor imaging and biological assessmentContinuous low-dose (metronomic) chemotherapy on rat prostate tumors evaluated using MRI in vivo and comparison with histologyDynamic contrast-enhanced MRI in clinical oncology: current status and future directions.Simultaneous T(1) and B(1) (+) mapping using reference region variable flip angle imaging.Rat tumor response to the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid as measured by dynamic contrast-enhanced magnetic resonance imaging, plasma 5-hydroxyindoleacetic acid levels, and tumor necrosis.Differentiation between benign and malignant breast lesions detected by bilateral dynamic contrast-enhanced MRI: a sensitivity and specificity study.Semi-quantitative parameter analysis of DCE-MRI revisited: monte-carlo simulation, clinical comparisons, and clinical validation of measurement errors in patients with type 2 neurofibromatosis.Differentiating treatment-induced necrosis from recurrent/progressive brain tumor using nonmodel-based semiquantitative indices derived from dynamic contrast-enhanced T1-weighted MR perfusion.High-field small animal magnetic resonance oncology studies.New Insights in Abdominal Pain in Paroxysmal Nocturnal Hemoglobinuria (PNH): A MRI Study.Early changes in apparent diffusion coefficient predict the quantitative antitumoral activity of capecitabine, oxaliplatin, and irradiation in HT29 xenografts in athymic nude mice.MRI for assessing antivascular cancer treatments.Assessment of antiangiogenic and antivascular therapeutics using MRI: recommendations for appropriate methodology for clinical trials.A pilot study to determine the timing and effect of bevacizumab on vascular normalization of metastatic brain tumors in breast cancer.MRI in the detection and management of breast cancer.A model-constrained Monte Carlo method for blind arterial input function estimation in dynamic contrast-enhanced MRI: I. SimulationsA simple, reproducible method for monitoring the treatment of tumours using dynamic contrast-enhanced MR imaging.The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations.
P2860
Q22252349-A688A949-982E-4AFB-A16E-AED2BDA89D97Q24612732-C180619A-D8B9-42F6-9749-8A87AD65C954Q26785606-D450CAED-6154-4A44-8B26-5F014C6E823CQ30485388-42175FD5-A98A-4756-8801-1B13BC6F09C1Q30575110-5E98F810-69A0-43A7-B74A-1F81E447FAF5Q30770588-680F3CE3-CBF8-4AD4-893B-71279DC4DCF2Q31153802-30E18766-6662-4F13-803C-4E044A017688Q33499951-E8B5D79E-44E2-4B3A-9A2C-D65187F443CEQ33507482-1FF08F2C-B244-490C-AC5D-2FE09FB080FCQ33614436-3E1F6CEC-AF25-4F89-9C6D-E4A509F56DA6Q33660443-82AB6DB0-4623-49A0-93D8-4454D164A8FFQ33686594-36A70984-DC87-4CB2-9F4E-84063DC8C45CQ33926377-69AA0E13-6226-4C19-B497-12CB69174931Q34078035-D6786B92-3D90-48A4-A50F-594251B1BB17Q34203923-6B74F7BC-FE06-40AE-BE0E-8D8F3CEE0E4EQ34269947-BEE359DA-E4FA-44D3-8935-B62E16BD0BF5Q34331739-17DA7C5C-9048-40FE-92E4-783F3E51ECBBQ34390068-C6BCEBDA-0FD3-4B22-8A97-B75FB1335014Q34391672-5D3BFE81-757D-4C32-8054-5F6CDFC183BCQ34496670-9B0DD33B-570B-4FD2-880E-D1A439677234Q34537722-C9581276-CFB5-4BFB-A957-882E382D54B3Q34635573-B2438335-386F-4E6A-B441-CB37D44B8C33Q34765364-D7CED69C-35B3-405D-8E11-C4795AA58A7EQ34768926-8E36061D-CF28-452E-AB85-1C85572616F7Q34918635-3DBA0640-28E9-4372-9BB0-C454B0967282Q34940714-FC487AA6-E615-41AC-8CC3-7FFB3A2AA622Q35052189-F12DC2DF-2DF9-42B0-A52E-8E1E753C35D3Q35062357-3FE3053A-800B-43FE-AC2E-D348934C04D3Q35110740-10543C73-68F0-4D43-9DC9-2FEC1E17AA16Q35170356-7B1144F1-D99E-4EEE-9B71-662987EC6327Q35312455-B2427171-ACC8-4360-B688-9673FCAAA828Q35511727-497C74A9-AC06-47D0-83DA-57669530E80BQ35812742-36444CDB-15E6-4561-A1B3-C10DDA6F5887Q35905005-BB700B9B-D8BD-4036-8279-2182002C712CQ35905017-D99F305B-2A46-44DB-A467-DC17D42C7174Q36076814-2B3BC833-38EE-4353-92C1-B2CE88A2F133Q36118389-5FAB283B-5ED2-4F50-AC77-9189848A4CD3Q36497440-13211684-3CFF-4B91-842D-A0D668E01994Q36614213-F9D0878C-7200-4CBF-81CA-7CD3FF19CF41Q36616812-53D6CEE3-8C79-4622-BB0C-9CC7F19726F5
P2860
Key factors in the acquisition of contrast kinetic data for oncology.
description
1999 nî lūn-bûn
@nan
1999 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Key factors in the acquisition of contrast kinetic data for oncology.
@ast
Key factors in the acquisition of contrast kinetic data for oncology.
@en
type
label
Key factors in the acquisition of contrast kinetic data for oncology.
@ast
Key factors in the acquisition of contrast kinetic data for oncology.
@en
prefLabel
Key factors in the acquisition of contrast kinetic data for oncology.
@ast
Key factors in the acquisition of contrast kinetic data for oncology.
@en
P2860
P1476
Key factors in the acquisition of contrast kinetic data for oncology.
@en
P2093
Evelhoch JL
P2860
P304
P356
10.1002/(SICI)1522-2586(199909)10:3<254::AID-JMRI5>3.0.CO;2-9
P577
1999-09-01T00:00:00Z